Mthera Pharma

Focus: Mthera Pharma is a Korean pharmaceutical company focused on botanicals and live therapeutics across neurology, cardiovascular, oncology, and women's health. The company is heavily dependent on XPOVIO (selinexor), which generates 97% of revenue.

Neurology Cardiovascular Oncology Women's Health

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Mthera Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Mthera Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

1 in 5yr

OLEPTRO

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

XPOVIO

Multiple Myeloma, Acute Myeloid Leukemia, Endometrial Cancer

$86M Part D

Peak

Help build intelligence for Mthera Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

XPOVIO is a peak-stage nuclear export inhibitor generating $86M in Part D spending across multiple oncology indications with LOE protection until 2035
Pipeline includes novel Phase 1/2 program MT101-5 for Parkinson's Disease, representing entry into neurology with high unmet need
Geographic diversity as Korean-headquartered company may offer unique market access and partnership opportunities in Asia-Pacific

Watch Out For

Extreme revenue concentration (97% XPOVIO) creates significant business risk if any commercial or regulatory challenge impacts the sole revenue driver
Minimal pipeline depth with only 2 total trials and 0 Phase 3 programs indicates limited near-term catalysts and long product development runway
Zero active job openings at time of analysis suggests company is not actively hiring, limiting near-term career opportunities

Generated by Claude from Mthera Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sole revenue engine representing 97% of company revenue; nuclear export inhibitor with 11-year patent protection.

DANAZOL

Endometriosis, Hereditary Angioedema

$2M Part D

Pre-Launch

ANDA candidate in women's health; modest current spending but addresses underserved endometriosis and angioedema markets.

Acetaminophen and Codeine Phosphate

Mild to Moderate Pain

Post-LOE

Post-LOE generic; limited differentiation in crowded analgesic market.

Products & Portfolio (4)

70 discontinued, 12 duplicate formulations not shown

Key Products by Revenue

Nuclear Export Inhibitors

2019

$86M Part D

LOE: 2035

Other Products (3)

Androgen Receptor Agonists

2007

PRAZOSIN HYDROCHLORIDE

Pipeline & Clinical Trials

MT101-5

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT05844787A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Phase 1

MT101-5

Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT06175767A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 86 approved products, 2 clinical trials

Top TAs: Cardiovascular, Neurology, Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Pre-Launch54 (63%)

Peak1 (1%)

LOE Approaching1 (1%)

Post-LOE30 (35%)

86 total products

Therapeutic Area Focus

Cardiovascular

18 marketed

Neurology

14 marketed2 pipeline

Immunology

5 marketed

Psychiatry

4 marketed

Women's Health

3 marketed

prazosin hydrochloride

CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a reflex tachycardia. Tolerance has not been observed to develop in long term therapy. Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and glomerular filtration rate. There is no measurable negative chronotropic effect. In clinical studies to date, prazosin hydrochloride has not increased plasma renin activity. In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure. Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. Bioavailability studies have demonstrated that the total absorption relative to the drug in a 20% alcoholic solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man. In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels.

Endocrinology

2 marketed